AGM/EGMApr 27, 2026, 04:13 PM
EYPT 2026 Annual Meeting Set for June 18; Key Proposals
AI Summary
EyePoint, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 18, 2026, where stockholders will vote on the election of eight directors, an increase of 4,900,000 shares for the 2023 Long-Term Incentive Plan, executive compensation, and auditor ratification. The company also provided a business update, highlighting significant progress with DURAVYU, including anticipated mid-2026 topline data for wet AMD Phase 3 trials and the initiation of DME Phase 3 trials in March 2026. EyePoint reported a strong financial position with over $300 million in cash and investments, extending its cash runway into Q4 2027.
Key Highlights
- EYPT to hold 2026 Annual Meeting of Stockholders virtually on June 18, 2026.
- Stockholders to vote on election of eight directors.
- Proposal to approve Amendment No. 3 to 2023 Long-Term Incentive Plan, increasing shares by 4,900,000.
- Advisory vote on executive compensation.
- Ratification of Deloitte & Touche LLP as independent auditor for FY2026.
- DURAVYU wet AMD Phase 3 trials (LUGANO, LUCIA) topline data expected mid-2026.
- DURAVYU DME Phase 3 trials (COMO, CAPRI) initiated March 2026, topline data Q4 2027.
- Ended 2025 with over $300 million in cash and investments, no debt, funding operations into Q4 2027.